Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus

Rheumatology International

Volumn 34, Issue 4, 2014, Pages 529-533

  AlE'ed, Ashwaq ^a   AlSonbul, Abdullah ^a   Al Mayouf, Sulaiman M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Arabia; Children; Efficacy; Nephritis; Rituximab; Safety; Saudi; Systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANCREAS ENZYME; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANKLE OSTEOMYELITIS; ANTIBIOTIC THERAPY; ARTHRITIS; ARTHROPATHY; ARTICLE; BACTEREMIA; CARDIOMYOPATHY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; ENZYME DEFECT; FEMALE; HAEMOPHILUS INFLUENZAE BACTEREMIA; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; KIDNEY FUNCTION; MALE; MEDICAL RECORD; MUCOCUTANEOUS LESION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEPHRITIS; ONSET AGE; OSTEOMYELITIS; PANCREATITIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; RECALCITRANT CHILDHOOD LUPUS; REFRACTORY ARTHRITIS; REFRACTORY THROMBOCYTOPENIA; SAUDI ARABIA; SCHOOL CHILD; SINGLE DRUG DOSE; SKIN DISEASE; SLEDAI; SOFT TISSUE FUNGAL INFECTION; SOFT TISSUE INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; DRUG COMBINATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRESCHOOL CHILD; REMISSION; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; AGE OF ONSET; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REMISSION INDUCTION; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897049354     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2896-8     Document Type: Article

References (20)

1. Grammer A, Lipsky P (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5(Suppl 4):S22-S27 (Pubitemid 38239913)
2. Lipsky P (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-766
3. Hoffman R (2004) T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113:4-13
4. Vachvanichsanong P, Dissaneewate P, McNeil E (2011) Twenty-two years' experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 96:44-49
5. Huggins J, Burnner H (2006) Targeting B cells in the treatment of childhood-onset systemic lupus erythmatosus. J Pediatr 148:571-573 (Pubitemid 43776911)
6. Thatayatikom A, White A (2006) Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18-24 (Pubitemid 41759438)
7. Sfikakis P, Boletis J, Tsokos G (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17:550-557 (Pubitemid 41527814)
8. Brunner H, Gladman D, Ibañez D, Urowitz M, Silverman E (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556-562 (Pubitemid 351294890)
9. Marks S, Patey S, Brogan S, Hasson N, Pilkington C, Woo P et al (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168-3174 (Pubitemid 41447099)
10. Nwobi O, Abitbol C, Chandar J, Seeherunvong W, Zilleruelo G (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23:413-419
11. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, French Pediatric-Onset SLE Study Group et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623-627
12. El-Hallak M, Binstadt B, Leichtner A, Bennett C, Neufeld E, Fuhlbrigge R et al (2007) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150:376-382 (Pubitemid 46437325)
13. Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N et al (1982) The 1982 revised criteria for the classification of the systemic lupus erythematosus. Arthritis Rheum 25:1271-1277 (Pubitemid 13221242)
14. Brunner H, Silverman E, To T, To T, Bombardier C, Feldman B (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436-444 (Pubitemid 34136581)
15. Gillis J, Dall'era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538-542 (Pubitemid 46682546)
16. García-Carrasco M, Jiménez-Hernández M, Escárcega R, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M et al (2009) Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 8:343-348
17. Gunnarsson I, Jonsdottir T (2013) Rituximab treatment in lupus nephritis - where do we stand? Lupus 22:381-389
18. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-38561
19. Abdwani R, Mani R (2009) Anti-CD20 monoclonal antibody in acute life threatening hemolytic anemia complicating childhood onset SLE. Lupus 15:460-464
20. Looney R, Anolik J, Campbell D, Felgar R, Young F, Arend L et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580-2589 (Pubitemid 39062719)